Compare · BSX vs STSS
BSX vs STSS
Side-by-side comparison of Boston Scientific Corporation (BSX) and Sharps Technology Inc. (STSS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and STSS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.16B, about 836.7x STSS ($77.9M).
- Over the past year, BSX is down 57.3% and STSS is down 80.1% - BSX leads by 22.9 points.
- BSX has hit the wire 4 times in the past 4 weeks while STSS has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for STSS).
- Company
- Boston Scientific Corporation
- Sharps Technology Inc.
- Price
- $44.98-0.02%
- $1.84+1.10%
- Market cap
- $65.16B
- $77.9M
- 1M return
- -10.83%
- +2.22%
- 1Y return
- -57.26%
- -80.13%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Sharps Technology Inc.
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
Latest BSX
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
Latest STSS
- Amendment: SEC Form SCHEDULE 13G/A filed by Sharps Technology Inc.
- SEC Form 10-Q filed by Sharps Technology Inc.
- Sharps Technology Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Levine Arthur
- Sharps Technology Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer
- Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol "SKYA"; Establishing Category-defining Agentic Finance Platform Serving Global South
- Amendment: SEC Form SCHEDULE 13G/A filed by Sharps Technology Inc.
- Sharps Technology Reports Continued Growth in Q1 2026 Highlighting Strengthened Balance Sheet and Strong Treasury Execution